Bannari Amman Sugars Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 23, 2025, 8:32 am

Quick Insight

Bannari Amman Sugars Ltd currently trades at a price of 3,750 with a market cap of 4,707 Cr. The company's P/E stands at 41.5, indicating a relatively high valuation compared to its industry peers. With an ROE of 6.04% and ROCE at 8.68%, the company's profitability metrics are moderate, reflecting room for improvement. The OPM of 11% suggests efficiency in operations. However, the low promoter holding of 58.69% raises questions about ownership stability. With a healthy ICR of 9.89x and a P/BV of 1.71x, the company showcases financial strength. Overall, investors should closely monitor operational efficiency and promoter shareholding for potential impact on future performance.

Competitors of Bannari Amman Sugars Ltd

All Competitor Stocks of Bannari Amman Sugars Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:01 pm

Below is a detailed analysis of the quarterly data for Bannari Amman Sugars Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 419.00 Cr.. The value appears to be declining and may need further review. It has decreased from 494.00 Cr. (Mar 2025) to 419.00 Cr., marking a decrease of 75.00 Cr..
• For Expenses, as of Jun 2025, the value is 382.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 441.00 Cr. (Mar 2025) to 382.00 Cr., marking a decrease of 59.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 16.00 Cr..
• For OPM %, as of Jun 2025, the value is 9.00%. The value appears to be declining and may need further review. It has decreased from 11.00% (Mar 2025) to 9.00%, marking a decrease of 2.00%.
• For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 17.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 55.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 31.00 Cr..
• For Tax %, as of Jun 2025, the value is 37.00%. The value appears to be increasing, which may not be favorable. It has increased from 36.00% (Mar 2025) to 37.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 20.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 12.16. The value appears to be declining and may need further review. It has decreased from 28.04 (Mar 2025) to 12.16, marking a decrease of 15.88.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:27 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 12:24 pm

Below is a detailed analysis of the balance sheet data for Bannari Amman Sugars Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,766.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,676.00 Cr. (Mar 2024) to 1,766.00 Cr., marking an increase of 90.00 Cr..
• For Borrowings, as of Mar 2025, the value is 150.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 486.00 Cr. (Mar 2024) to 150.00 Cr., marking a decrease of 336.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 297.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 260.00 Cr. (Mar 2024) to 297.00 Cr., marking an increase of 37.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,226.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,435.00 Cr. (Mar 2024) to 2,226.00 Cr., marking a decrease of 209.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,189.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,071.00 Cr. (Mar 2024) to 1,189.00 Cr., marking an increase of 118.00 Cr..
• For CWIP, as of Mar 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 112.00 Cr. (Mar 2024) to 11.00 Cr., marking a decrease of 101.00 Cr..
• For Investments, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,022.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,249.00 Cr. (Mar 2024) to 1,022.00 Cr., marking a decrease of 227.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,226.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,435.00 Cr. (Mar 2024) to 2,226.00 Cr., marking a decrease of 209.00 Cr..

Notably, the Reserves (1,766.00 Cr.) exceed the Borrowings (150.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Bannari Amman Sugars Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 121.46. This value is within the healthy range. It has increased from 114.35 (Mar 23) to 121.46, marking an increase of 7.11.
• For Diluted EPS (Rs.), as of Mar 24, the value is 121.46. This value is within the healthy range. It has increased from 114.35 (Mar 23) to 121.46, marking an increase of 7.11.
• For Cash EPS (Rs.), as of Mar 24, the value is 167.38. This value is within the healthy range. It has decreased from 173.39 (Mar 23) to 167.38, marking a decrease of 6.01.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 1,346.44. It has increased from 1,237.58 (Mar 23) to 1,346.44, marking an increase of 108.86.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 1,346.44. It has increased from 1,237.58 (Mar 23) to 1,346.44, marking an increase of 108.86.
• For Dividend / Share (Rs.), as of Mar 24, the value is 12.50. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 23) which recorded 12.50.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 1,770.63. It has decreased from 2,014.06 (Mar 23) to 1,770.63, marking a decrease of 243.43.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 249.69. This value is within the healthy range. It has decreased from 273.99 (Mar 23) to 249.69, marking a decrease of 24.30.
• For PBIT / Share (Rs.), as of Mar 24, the value is 203.76. This value is within the healthy range. It has decreased from 214.95 (Mar 23) to 203.76, marking a decrease of 11.19.
• For PBT / Share (Rs.), as of Mar 24, the value is 178.52. This value is within the healthy range. It has increased from 175.61 (Mar 23) to 178.52, marking an increase of 2.91.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 121.46. This value is within the healthy range. It has increased from 114.35 (Mar 23) to 121.46, marking an increase of 7.11.
• For PBDIT Margin (%), as of Mar 24, the value is 14.10. This value is within the healthy range. It has increased from 13.60 (Mar 23) to 14.10, marking an increase of 0.50.
• For PBIT Margin (%), as of Mar 24, the value is 11.50. This value is within the healthy range. It has increased from 10.67 (Mar 23) to 11.50, marking an increase of 0.83.
• For PBT Margin (%), as of Mar 24, the value is 10.08. This value is within the healthy range. It has increased from 8.71 (Mar 23) to 10.08, marking an increase of 1.37.
• For Net Profit Margin (%), as of Mar 24, the value is 6.85. This value is within the healthy range. It has increased from 5.67 (Mar 23) to 6.85, marking an increase of 1.18.
• For Return on Networth / Equity (%), as of Mar 24, the value is 9.02. This value is below the healthy minimum of 15. It has decreased from 9.23 (Mar 23) to 9.02, marking a decrease of 0.21.
• For Return on Capital Employeed (%), as of Mar 24, the value is 13.71. This value is within the healthy range. It has decreased from 15.09 (Mar 23) to 13.71, marking a decrease of 1.38.
• For Return On Assets (%), as of Mar 24, the value is 6.25. This value is within the healthy range. It has increased from 6.07 (Mar 23) to 6.25, marking an increase of 0.18.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 23) to 0.03, marking a decrease of 0.07.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.28. This value is within the healthy range. It has decreased from 0.37 (Mar 23) to 0.28, marking a decrease of 0.09.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.92. It has decreased from 1.03 (Mar 23) to 0.92, marking a decrease of 0.11.
• For Current Ratio (X), as of Mar 24, the value is 2.09. This value is within the healthy range. It has increased from 2.04 (Mar 23) to 2.09, marking an increase of 0.05.
• For Quick Ratio (X), as of Mar 24, the value is 0.32. This value is below the healthy minimum of 1. It has decreased from 0.33 (Mar 23) to 0.32, marking a decrease of 0.01.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.55. This value is below the healthy minimum of 4. It has decreased from 1.72 (Mar 23) to 1.55, marking a decrease of 0.17.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 10.29. This value is below the healthy minimum of 20. It has increased from 8.74 (Mar 23) to 10.29, marking an increase of 1.55.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 7.46. This value is below the healthy minimum of 20. It has increased from 5.76 (Mar 23) to 7.46, marking an increase of 1.70.
• For Earning Retention Ratio (%), as of Mar 24, the value is 89.71. This value exceeds the healthy maximum of 70. It has decreased from 91.26 (Mar 23) to 89.71, marking a decrease of 1.55.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 92.54. This value exceeds the healthy maximum of 70. It has decreased from 94.24 (Mar 23) to 92.54, marking a decrease of 1.70.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 9.89. This value is within the healthy range. It has increased from 6.97 (Mar 23) to 9.89, marking an increase of 2.92.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 5.81. This value is within the healthy range. It has increased from 3.91 (Mar 23) to 5.81, marking an increase of 1.90.
• For Enterprise Value (Cr.), as of Mar 24, the value is 3,372.02. It has decreased from 3,986.56 (Mar 23) to 3,372.02, marking a decrease of 614.54.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.52. This value is within the healthy range. It has decreased from 1.58 (Mar 23) to 1.52, marking a decrease of 0.06.
• For EV / EBITDA (X), as of Mar 24, the value is 10.77. This value is within the healthy range. It has decreased from 11.60 (Mar 23) to 10.77, marking a decrease of 0.83.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.30. This value is within the healthy range. It has decreased from 1.35 (Mar 23) to 1.30, marking a decrease of 0.05.
• For Retention Ratios (%), as of Mar 24, the value is 89.70. This value exceeds the healthy maximum of 70. It has decreased from 91.25 (Mar 23) to 89.70, marking a decrease of 1.55.
• For Price / BV (X), as of Mar 24, the value is 1.71. This value is within the healthy range. It has decreased from 2.20 (Mar 23) to 1.71, marking a decrease of 0.49.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.30. This value is within the healthy range. It has decreased from 1.35 (Mar 23) to 1.30, marking a decrease of 0.05.
• For EarningsYield, as of Mar 24, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 23) to 0.05, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness